Ipamorelin is a selective growth-hormone secretagogue that acts through the ghrelin receptor at the pituitary gland. Its key catalogue distinction is selectivity: it is positioned as a cleaner GH-release signal than older GHRPs, with less emphasis on cortisol and prolactin activation. It can be selected independently or combined with CJC-1295 No DAC, which works through a different but complementary pathway.
Ipamorelin is a peptide that stimulates the pituitary gland to release growth hormone. It is classified as a secretagogue because it promotes the body’s own secretion rather than supplying GH directly. It acts primarily on the ghrelin receptor.
GH signaling is linked to deep sleep, muscle recovery, training adaptation, and nighttime repair. For this reason, Ipamorelin is positioned to support recovery and rest in active individuals. However, it does not, on its own, correct insufficient sleep or overtraining.
The guide distinguishes it because it stimulates GH with a lower expected impact on cortisol and prolactin than other GHRPs. That selectivity is part of its commercial appeal. It does not imply a total absence of effects, nor does it eliminate the need to assess the hormonal context.
It can be part of a body composition strategy by supporting endogenous GH, recovery, and sleep quality. However, it does not reduce appetite or replace an energy deficit, protein intake, or strength training. Its role is to support the environment, not to do the heavy lifting.
Ipamorelin utilizes the ghrelin receptor, while CJC-1295 mimics GHRH. Both converge on GH release but originate from different signals. For this reason, they can be used separately or combined in a complementary manner.
It simply allows for a more precise assessment and adjustment of the Ipamorelin signal. When combined with CJC-1295, it offers two complementary stimuli and a more comprehensive approach. This combination makes sense when the objective justifies it, rather than as an automatic rule.
Ipamorelin is a ghrelin receptor agonist and a selective secretagogue. Tesamorelin is a stabilized GHRH analog with a profile more closely linked to visceral fat and body composition. They are not versions of increasing potency, but rather tools with distinct profiles.
The 5 mg and 10 mg figures indicate the total amount of product contained in each vial, not a recommendation for use.
A larger presentation may offer a greater quantity or more flexibility, but it is not automatically the right choice.
The choice should depend on the objective, the protocol format, and individual assessment.
You will be kept up to date with all our latest news.
